UroGen Pharma Ltd
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 2 weeks.
- Its last 8 Sell calls were actually followed by a +33% average gain three months out - this one has bounced back faster than the signal expected.
- Recent price momentum is -14.8% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 10.4% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 5 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation B-
How expensive the stock is versus earnings, sales and its own 5-year history.
| Forward P/E | 10.1x | Better than 79% |
| Price / Sales | 5.1x | Better than 22% |
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D+
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 88.7% | Better than 96% |
| Operating margin | -113.7% | Better than 7% |
| Net margin | -139.8% | Better than 6% |
| Return on equity | -211.6% | Better than 3% |
| Return on invested capital | -208.3% | Better than 1% |
Momentum C
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -41.0% | Better than 10% |
| 6-month return | -4.3% | Better than 48% |
| 12-month return (ex latest month) | 33.3% | Better than 72% |
| Distance below 52-week high | 45.6% | Better than 23% |
Financial Health D+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 4.0x | Better than 81% |
| Debt to assets | 64.0% | Better than 7% |
| Interest coverage | -9.0x | Better than 14% |
Analyst View A
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 125.0% | Better than 88% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 31.73
- Open
- 31.15
- Day range
- 27.57 - 31.90
- Avg price
- 29.63
- Volume
- 2.40M
- Turnover
- 71.09M
- Turnover ratei
- 5.51%
- Volume ratioi
- 1.13
- Amplitudei
- 13.65%
- 52-week rangei
- 16.50 - 50.81
Valuation
- P/Ei
- -8.67
- P/E (TTM)i
- -21.11
- P/Bi
- -10.83
- EPSi
- -3.19
- Book value / shi
- -2.55
- Net profit
- -156.46M
- Net assets
- -125.22M
Share structure
- Market cap
- 1.36B
- Float capi
- 1.20B
- Shares out
- 49.05M
- Float sharesi
- 43.57M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2017-05-04
45.6% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-2.72M net over the window
Short interest
- Shares short
- 5.11M
- % of floati
- 10.45%
- Days to coveri
- 5.09
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of UroGen Pharma Ltd (URGN)?
UroGen Pharma Ltd last traded at 27.65. This page shows a periodic quote snapshot. Check the displayed quote time.
What is UroGen Pharma Ltd's market cap?
About 1.36B.
What is the P/E ratio of UroGen Pharma Ltd?
The trailing twelve-month P/E is -21.11. The Valuation tab shows it against the stock's own five-year range.
Does UroGen Pharma Ltd pay a dividend?
UroGen Pharma Ltd does not currently pay a regular dividend.
Is UroGen Pharma Ltd a buy according to analysts?
The consensus of 5 analysts is a Buy rating, with an average 12-month price target of 62.20, which implies 125.0% upside from the current price. This is not investment advice.
What is UroGen Pharma Ltd's StockVane Quant Rating?
The StockVane Momentum strategy currently rates UroGen Pharma Ltd a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 20:02:23 · For reference only, not investment advice and not tailored to your situation.
UroGen Pharma Ltd discussion 0 comments